FindTrial
Sign In

CD19.CAR T cells

DRUG3 trials

Sponsors

Universitaetsklinikum Heidelberg AöR, University Hospital Heidelberg

Conditions

ANCA-associated VasculitisAccute lymphoblastic leukemia recurrentAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, PediatricChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaMantle Cell Lymphoma

Phase 1

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
RecruitingNCT03676504
University Hospital HeidelbergAcute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia +3
Start: 2018-09-07End: 2027-12-31Target: 68Updated: 2024-07-29
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]
RecruitingCTIS2024-516832-82-00
Universitaetsklinikum Heidelberg AöRAccute lymphoblastic leukemia recurrent, Non-Hodgkin´s lymphoma NOS refractory
Start: 2018-08-27Target: 63Updated: 2024-09-19
Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
Not yet recruitingCTIS2024-519592-26-00
Universitaetsklinikum Heidelberg AöRANCA-associated Vasculitis, anti-Synthetase Syndrome or other autoimmune diseases, seropositive Rheumatoid Arthritis +2
Target: 10Updated: 2026-08-03

Related Papers

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses
Nature Communications2026-07-29
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
Leukemia2024-08-2732 citations
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
2023-07-2226 citations
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
BMJ Open2020-02-0149 citations
Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients
Blood2019-11-1346 citations
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
BMJ Open2019-05-0140 citations